GulfBase Live Support
JULPHAR, one of the largest pharmaceutical manufacturers in the Middle East and Africa, announced its first quarter 2018 financial results. The Ras Al Khaima company reported first quarter 2018 sales of AED264.0 million and a net profit of AED18.4 million, after implementation of new Accounting Standard IFRS 9 and IFRS 15.
Julphar’s Q1 2018 results were announced at a Board of Directors’ meeting, which was chaired by Sheikh Faisal Bin Saqr Al Qasimi, chairman of the Board of Julphar.
Jerome Carle, general manager of Julphar, said: “Julphar delivered a good first quarter performance, in line with our internal target. In the first three months of 2018, we made significant progress in UAE and Levant and we resumed our operations in Libya.
“This is a good set of results showing the progress we are making. We continued to strengthen our positions through new product launches in Cardiology and Respiratory, and the execution of our long-term strategy in Consumer Healthcare. We also improved our working capital KPI, after rolling out several strategic initiatives last year.
“We are well-positioned for a strong and profitable second quarter and remain focused on delivering shareholder value through organic and strategic growth opportunities. In combination with our expansion initiatives in place such as Saudi Arabia and Africa, we believe there are firm drivers for our growth in 2018.”
Earlier, it was announced that Julphar had been ranked No. 1 pharmaceutical company in the UAE by IMS Health, reflecting a strong double digit sales growth versus 2017. This year, the company plans to launch 25 new products in the UAE and register 200 new products in the region.
Carle added: “We are off to a strong start in 2018. We have reached the number one position in the UAE in terms of market share, our new management team is now fully on board and we are building up a solid products pipeline.”
Julphar is looking at several mergers and acquisitions across the Middle East and African markets and may announce its first deal as soon as the third quarter of this year.
“We are working
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, reported first quarter 2018 net profit of Dh18.4 million and sales of Dh264.0 million, after implementation of
Julphar, a leading pharmaceutical manufacturer in the region, has been ranked as the number one pharmaceutical company in the UAE by IMS Health February 2018 panel, reflecting a strong double digit s
Amid an ongoing restructuring, Dubai-listed retailer Marka has seen its losses narrow in the second quarter, while also seeing its revenue slip. The company did manage, however, to post a gross profi
Batelco, the leading digital solutions provider in Bahrain, is set to offer a new high-speed LTE Data Roaming services package with options including a one-day data roaming in the GCC for only BD5 ($
Nakheel, a leading global developer, said it has registered a net profit of Dh2.51 billion ($683 million) for the first six months of the year compared to Dh2.61 billion ($710 million) for the same p
Leading property developer Emaar has registered a revenue of Dh11.47 billion ($3.12 billion) for the first half of the year, up 46 per cent compared to Dh7.86 billion ($2.14 billion) last year led by
Leveraging its unique ability to expand value for its customers while also contributing to Saudi Vision 2030, SABIC, a global leader in the chemical industry, is investing in new applications and met